Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Mengqiu Tang"'
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
ABSTRACT Background Endoscopic submucosal dissection (ESD) is a widely utilized treatment for early esophageal cancer. However, the rising incidence of postoperative esophageal stricture poses a significant challenge, adversely affecting patients' qu
Externí odkaz:
https://doaj.org/article/6b827f88fcbc4b689753e51685644d67
Autor:
Tian Chen, Mengqiu Tang, Yang Zhou, Zhepei Wang, Shiwei Li, Hongcai Wang, Yangfang Lu, Jinguo Wang, Weiyu Shen
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundStudies on the prognostic factors for patients with brain oligo-metastasis treated with fractionated stereotactic radiotherapy (FSRT) usually focus on the size of metastatic tumor and radiation dose. Some inflammatory indicators have predic
Externí odkaz:
https://doaj.org/article/5ef6757677294165a98c0c955c1c5812
Publikováno v:
Lipids in Health and Disease, Vol 20, Iss 1, Pp 1-10 (2021)
Abstract Background Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Findings from an ALTER0303 phase III trial revealed that this dr
Externí odkaz:
https://doaj.org/article/6fe58de71bfe4ffa81cf84773b662752
Publikováno v:
Disease Markers. 2022:1-16
Background. A phase III randomized multicenter trial (ALTER0303) reported anlotinib to be significantly beneficial to patient survival. An array of inflammatory biomarkers, such as neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd6ec9cf7f6b5a737e2c1d5288e9a520
https://doi.org/10.1155/2022/5879137
https://doi.org/10.1155/2022/5879137
Autor:
Tian Chen, Mengqiu Tang, Xiaoyu Xu, Gaofeng Liang, Zhenfei Xiang, Yi Lu, Chen Wang, Weiyu Shen
Publikováno v:
Journal of Clinical Laboratory Analysis. 36
According to the randomized multicenter phase II trial (ALTER1202), anlotinib has been approved as a third-line therapy for advanced small-cell lung cancer (SCLC). Some studies showed the predictive function of inflammatory markers, including neutrop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15b1cd6bf8cb0059421c83bd08fec1b9
https://doi.org/10.1002/jcla.24772
https://doi.org/10.1002/jcla.24772
Autor:
Tian Chen, Mengqiu Tang, Yang Zhou, Zhepei Wang, Shiwei Li, Hongcai Wang, Yangfang Lu, Jinguo Wang, Weiyu Shen
Publikováno v:
Frontiers in Oncology; 2023, p1-11, 11p
Publikováno v:
Journal of clinical laboratory analysis. 36(4)
Anlotinib is a third-line or further therapy for advanced non-small-cell lung cancer (NSCLC). However, the lack of simple biomarkers to predict the curative effect of anlotinib creates significant unmet needs in exploring the markers. This study aime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c11eab7c5a2beece936f7d1c16521ee
https://pubmed.ncbi.nlm.nih.gov/35179795
https://pubmed.ncbi.nlm.nih.gov/35179795
Publikováno v:
Cancer Management and Research
Chen Wang,1,* Jiaqi Tong,2,* Mengqiu Tang,3 Yunyun Lu,3 Gaofeng Liang,4 Zhanchun Zhang,3 Tian Chen3 1Department of Gastroenterology, Ningbo Medical Center, Lihuili Hospital, Ningbo, People’s Republic of China; 2Department of Hematology, Ningbo Medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::120ec6155ab99291da63c1f924b69ba1
https://www.dovepress.com/pretreatment-neutrophil-to-lymphocyte-ratio-and-platelet-to-lymphocyte-peer-reviewed-article-CMAR
https://www.dovepress.com/pretreatment-neutrophil-to-lymphocyte-ratio-and-platelet-to-lymphocyte-peer-reviewed-article-CMAR
Publikováno v:
Traditional Medicine Research. 7:32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7396349be8e738f34f38df348a562fe6
https://doi.org/10.53388/tmr20221022002
https://doi.org/10.53388/tmr20221022002